Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Trial to Investigate the Safety and Tolerability of Single and Multiple Oral Doses of DNL747 in Healthy Subjects

Next Previous
Trial Profile

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single-Center Clinical Trial to Investigate the Safety and Tolerability of Single and Multiple Oral Doses of DNL747 in Healthy Subjects

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs DNL-747 (Primary)
  • Indications Alzheimer's disease; Amyotrophic lateral sclerosis; Multiple sclerosis
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Denali Therapeutics Inc

    • Most Recent Events

    • 19 Nov 2018 Results presented in a Denali Therapeutics media release.
    • 11 Nov 2018 New trial record
    • 08 Nov 2018 According to a Denali Therapeutics media release, data from this trial will be presented at the Denali 2018 R&D Day on December 10, 2018.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top